The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study
Abstract
BACKGROUND The incidence of cancer (excluding non-melanomatous skin cancers) is projected to rise from 17·0 million to 26·0 million between 2018 and 2040. A large proportion of these patients would be likely to derive benefit from chemotherapy, but no studies so far have quantified current and projected global chemotherapy demands. We aimed to estimate changes in national, regional, and global demands for first-course chemotherapy and the cancer physician workforce between 2018 and 2040 if all patients were treated according to best-practice evidence-based guidelines. METHODS Data for the incidence of 29 types of cancer in 183 countries in 2018, and projections of incidence in 2040, were obtained from GLOBOCAN 2018. Optimal chemotherapy utilisation from evidence-based guidelines was applied to these incidence data to generate the number of new patients requiring first-course chemotherapy in 2018 and 2040. We then estimated the corresponding cancer physician workforce required to deliver this chemotherapy (on the basis of physicians seeing 150 new patients requiring chemotherapy per year). We did sensitivity analyses to investigate how cancer stage at presentation affected chemotherapy demands. We also did sensitivity analyses to explore changes to workforce requirements if each physician was seeing 100 new patients requiring chemotherapy per year or 300 new patients requiring chemotherapy per year. FINDINGS Between 2018 and 2040, the number of patients requiring first-course chemotherapy annually will increase from 9·8 million to 15·0 million, a relative increase of 53%. The estimated proportion of patients needing chemotherapy who reside in low-income or middle-income countries was 63% (6 162 240 of 9 782 783) in 2018, and will be 67% (10 071 049 of 14 984 560) in 2040. The most common indications for chemotherapy worldwide in 2040 will be lung cancer (accounting for 2 455 137 [16·4%] of 14 984 560 cases eligible for chemotherapy), breast cancer (1 898 740 [12·7%]), and colorectal cancer (1 678 153 [11·1%]). We estimated that, in 2018, 65 000 cancer physicians were required worldwide to deliver optimal chemotherapy-a figure that we estimate will rise to 100 000 by 2040 (with estimates ranging from from 50 000 to 150 000, depending on workload). INTERPRETATION Strategic investments in chemotherapy service provision and cancer physicians are needed to meet the projected increased demand for chemotherapy in 2040. FUNDING None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Self-citationCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citationExpanding global access to radiotherapy
Atun, R., Jaffray, D. A., Barton, M. B., Bray, F., Baumann, M., Vikram, B., Hanna, T. P., Knaul, F. M., Lievens, Y., Lui, T. Y. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00222-3 · Cited by 1,112
Self-citationExpansion of cancer care and control in countries of low and middle income: a call to action
Farmer, P., Frenk, J., Knaul, F. M., Shulman, L. N., Alleyne, G., Armstrong, L., Atun, R., Blayney, D., Chen, L., Feachem, R., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61152-x · Cited by 794
Global cancer surgery: delivering safe, affordable, and timely cancer surgery
Sullivan, R., Alatise, O. I., Anderson, B. O., Audisio, R., Autier, P., Aggarwal, A., Balch, C., Brennan, M. F., Dare, A., D'Cruz, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00223-5 · Cited by 697
Iqbal, J., Ginsburg, O., Rochon, P. A., Sun, P., & Narod, S. A. (2015) · JAMA · doi:10.1001/jama.2014.17322 · Cited by 614
Future supply and demand for oncologists: challenges to assuring access to oncology services
Erikson, C., Salsberg, E., Forte, G., Bruinooge, S., & Goldstein, M. (2007) · Journal of Oncology Practice · doi:10.1200/jop.0723601 · Cited by 528
Management of gastric cancer in Asia: resource-stratified guidelines
Shen, L., Shan, Y.-S., Hu, H.-M., Price, T. J., Sirohi, B., Yeh, K.-H., Yang, Y.-H., Sano, T., Yang, H.-K., Zhang, X., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70436-4 · Cited by 461
Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis
Jedy-Agba, E., McCormack, V., Adebamowo, C., & dos-Santos-Silva, I. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30259-5 · Cited by 401
Ayanian, J. Z., Zaslavsky, A. M., Fuchs, C. S., Guadagnoli, E., Creech, C. M., Cress, R. D., O’Connor, L. C., West, D. W., Allen, M. E., Wolf, R. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.178 · Cited by 308
Cited by
A comprehensive review on time-tested anticancer drug doxorubicin
Sritharan, S., & Sivalingam, N. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119527 · Cited by 487
Cancer in sub-Saharan Africa: a Lancet Oncology Commission
Ngwa, W., Addai, B. W., Adewole, I., Ainsworth, V., Alaro, J., Alatise, O. I., Ali, Z., Anderson, B. O., Anorlu, R., Avery, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00720-8 · Cited by 400
Recent advances in polymeric core–shell nanocarriers for targeted delivery of chemotherapeutic drugs
Yang, X., & Xie, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121094 · Cited by 33
Metadata
- Authors
- Wilson, B. E., Jacob, S., Yap, M. L., Ferlay, J., Bray, F., & Barton, M. B.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 20
- Issue
- 6
- Pages
- 769-780
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2944757226
- Cited by
- 270
- References
- 28
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30163-9
- The paper
- Wilson, B. E., Jacob, S., Yap, M. L., Ferlay, J., Bray, F., & Barton, M. B. (2019). Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30163-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.